May 13, 2025 09:17 AM EDTUpdated 12:51 PM
Pharma

Watch Post-Hoc Live: Trump's 'most fa­vored na­tion' plan to cut drug prices

Drew Armstrong

Executive Editor

To­day on Post Hoc Live, Drew Arm­strong talked with Nick Ship­ley, the for­mer top lob­by­ist for the biotech in­dus­try, to break down Pres­i­dent Trump’s “most …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

TIG­IT grave­yard ex­pands as GSK drops late-stage as­set with iTeos

Up­dat­ed: To spin off or not to spin off? Gala­pa­gos backpedals on sep­a­ra­tion plans, CEO Paul Stof­fels ex­its ear­ly

Bay­er starts 2025 by cut­ting 2,000 jobs as it homes in on year-end re­haul tar­get

Dutch biotech gets $146M for late-stage tri­als in three meta­bol­ic dis­or­ders

Arc­turus to pri­or­i­tize mR­NA ther­a­peu­tics in bid to boost rare dis­ease pro­grams

Unit­ed­Health Group CEO An­drew Wit­ty steps down

A service from the Financial Times